sur SENSORION (EPA:ALSEN)
Sensorion Reports 2025 Results and Corporate Updates
Sensorion, a biotechnology company focused on hearing loss therapies, announced its full-year 2025 financial results and corporate updates. Key highlights include progress in their GJB2-GT gene therapy program, with regulatory interactions in place. The CTA submission is expected in the first half of 2026. Additionally, the ongoing SENS-501 trial is set to deliver six-month efficacy data in Q1 2026.
The company strengthened its financial position through a €60 million financing, which includes a €20 million strategic investment from Sanofi, extending its cash runway to mid-2027. Operationally, Sensorion's pipeline includes gene therapy programs like SENS-501 for otoferlin deficiency and SENS-401 for hearing loss prevention and treatment.
Amit Munshi serves as interim CEO following Nawal Ouzren's departure due to personal reasons.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de SENSORION